Heterobifunctional AR-BRD4 Compounds for Cancer Cell Death
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are not effective for all patients and often have substantial adverse side effects, necessitating new therapies that achieve an anti-cancer effect through a different mechanism.
Innovation Solution
Development of heterobifunctional compounds, represented by Formulas I and II, which can be administered to patients to treat cancer by targeting specific cellular mechanisms, such as those involving androgen receptor (AR) signaling, leading to cancer cell death.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer therapies are used, then cancer treatment is achieved through DNA alkylation, topoisomerase inhibition, or mitotic inhibition, but the treatments are not effective for all patients and have substantial adverse side effects
Solution Approach 1:
The heterobifunctional compound is divided into two distinct functional moieties: an androgen receptor (AR) binding domain and a bromodomain 4 (BRD4) binding domain, connected by a linker. This segmentation allows the compound to simultaneously target two different proteins involved in prostate cancer pathogenesis, achieving a novel mechanism of action that differs from conventional single-target therapies, thereby improving effectiveness while potentially reducing side effects through more specific dual-target inhibition
Solution Approach 2:
The compound represents a composite molecular structure combining two different pharmacophores (AR binder and BRD4 binder) into a single heterobifunctional molecule. This composite approach creates a new therapeutic agent with dual functionality, addressing the limitation of current monofunctional therapies and providing a novel mechanism that may overcome treatment resistance and reduce adverse effects
2Reliability
If new therapies with different mechanisms are developed, then effectiveness against resistant cancers is improved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent merges two separate therapeutic functions (AR inhibition and BRD4 inhibition) into a single heterobifunctional compound. By combining these activities in one molecule rather than requiring separate drugs, the approach simplifies the therapeutic regimen while maintaining the complexity-beneficial dual mechanism of action, potentially improving patient compliance and treatment effectiveness against resistant cancers
Solution Approach 2:
The heterobifunctional compound exhibits multi-functionality by simultaneously binding to and inhibiting both the androgen receptor and bromodomain 4. This universal design allows a single agent to address multiple pathways involved in prostate cancer progression and resistance, providing broad effectiveness against various cancer types and resistant strains without requiring multiple separate therapies
Data Source
AI summary
The invention provides heterobifunctional compounds which may bind to both an androgen receptor and BRD4 (bromodomain-containing protein 4). Also provided are pharmaceutical compositions comprising the same and their use in treating disease, CN such as cancer.